01 Growing Adoption of AI-Based In-Clinic Cytology The veterinary point of care diagnostics market is increasingly incorporating artificial intelligence into cytology workflows that previously depended heavily on specialist interpretation. Digital imaging combined with AI can analyze cellular samples inside veterinary practices and provide standardized results while the animal is still at the clinic. Faster interpretation can help veterinarians make treatment decisions without sending every specimen to an external laboratory. AI-supported cytology is therefore becoming an important part of veterinary point of care diagnostics market trends. In January 2026, IDEXX Laboratories expanded its inVue Dx Cellular Analyzer with AI-supported applications for veterinary cytology. The platform can deliver results in approximately 10 minutes and uses a reference database containing more than 5 million annotated cellular images.
02 Increasing Development of Portable Molecular Diagnostics Veterinary molecular testing is moving closer to animals through compact systems capable of detecting pathogen DNA or RNA outside centralized laboratories. Portable PCR-based technologies can help veterinarians identify infectious diseases rapidly and initiate treatment, isolation, or herd-management measures without waiting for samples to travel to reference facilities. This is particularly valuable for livestock, equine, and field veterinary applications. Decentralized molecular testing is consequently expanding the veterinary point of care diagnostics industry beyond conventional clinic-based analyzers. In May 2025, Biomeme expanded its portable veterinary molecular-testing capabilities through its Franklin real-time PCR platform, which weighs approximately 1.2 kg and supports 9 reaction wells with multiplex detection of as many as 27 targets in a single instrument run.
01 Increasing Veterinary Visits Are Raising Demand for Immediate Test Results Veterinarians frequently need chemistry, hematology, urinalysis, and other diagnostic information during consultations to distinguish diseases with similar clinical signs. Point-of-care testing reduces dependence on sample transportation and allows diagnosis and treatment planning to occur within the same visit. Faster results are particularly valuable in emergency cases and when animals require immediate medication or surgery. Increasing diagnostic intensity in veterinary practice is therefore strengthening veterinary point of care diagnostics market demand.
01 High Consumable Costs Can Limit Testing Volumes in Smaller Practices Point-of-care analyzers require recurring expenditure on cartridges, slides, reagents, controls, and other proprietary consumables in addition to the initial equipment investment. Small veterinary practices may process relatively few samples, making the per-test economics less attractive than sending non-urgent specimens to centralized laboratories. Consumables can also expire if testing volumes are insufficient. Cost-per-test considerations can consequently restrain veterinary point of care diagnostics market growth among lower-volume clinics.
01 Expansion of Point-of-Care Testing for Livestock Reproductive Management Livestock producers need rapid information about reproductive status to optimize breeding schedules, calving intervals, and herd productivity. Point-of-care hormone testing can allow veterinarians and producers to make reproductive decisions without waiting for laboratory turnaround, creating a separate application from infectious-disease diagnosis. Reproductive diagnostics can therefore help suppliers increase veterinary point of care diagnostics market share.
01 Maintaining Reliable Results Across Multiple Animal Species Diagnostic values can vary substantially among dogs, cats, horses, cattle, and other animals because each species has different reference intervals, cellular characteristics, and biomarker concentrations. A test developed around one species cannot automatically provide equivalent clinical accuracy in another. Manufacturers therefore need species-specific validation, calibration, reference data, and quality controls while keeping systems practical for everyday veterinary use. Maintaining consistent diagnostic performance across diverse animals remains a major challenge as veterinary point of care diagnostics market size expands.
May 2026 HORIBA launched the Yumivet veterinary diagnostics brand and VH2500 hematology analyzer, offering multispecies testing with 57 parameters, including CBC with 9-part differential, reticulocyte analysis, and dual platelet measurement methods.
April 2026 Zoetis expanded VetScan OptiCell capabilities by adding cellular hemoglobin concentration mean (CHCM), making it the first point-of-care veterinary hematology analyzer to offer the parameter previously associated with reference laboratory testing.
January 2026 IDEXX Laboratories announced the rollout of fine-needle aspirate cytology on the IDEXX inVue Dx Cellular Analyzer, enabling rapid in-clinic evaluation of canine skin masses and mast cell tumor detection. The capability had begun rolling out in late Q4 2025.
November 2025 Zoetis acquired Veterinary Pathology Group, expanding its veterinary diagnostic capabilities and pathology services across the UK and Ireland.